NCT01968538
Enrolling by Invitation
N/A
A Pilot Study to Establish a Standardized Protocol for Omic Analysis of Patients With Clinically Localized Prostate Cancer Receiving Radiation Therapy
ConditionsProstate Cancer
Overview
- Phase
- N/A
- Intervention
- Not specified
- Conditions
- Prostate Cancer
- Sponsor
- Georgetown University
- Enrollment
- 400
- Locations
- 1
- Primary Endpoint
- molecular changes in biofluid
- Status
- Enrolling by Invitation
- Last Updated
- 3 years ago
Overview
Brief Summary
Prostate cancer is a common disease in men treated using surgery, radiation therapy and/or hormonal therapy. Clinical prognosis relates to stage and grade of disease. Recent advances in omic analysis may offer additional information to the physician about prognosis and radiation response. We propose to establish a protocol to incorporate omic analysis into the evaluation and treatment of patients with prostate cancer.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Males who are older than 18 years old,
- •with clinically localized prostate cancer
- •are receiving radiation therapy
Exclusion Criteria
- Not provided
Outcomes
Primary Outcomes
molecular changes in biofluid
Time Frame: 5 years
Study Sites (1)
Loading locations...
Similar Trials
Completed
N/A
Treatment Patterns Among Patients With Prostate Cancer Prior to Diagnosis of a Castration-resistant StateProstate CancerNCT01560858Ipsen407
Completed
Phase 1
Study to Evaluate a New Method to Detect Residual Tumours During Surgery for Prostate Cancer Using Confocal MicroscopyProstate CancerNCT06398470University College, London21
Withdrawn
N/A
Detection of Prostate Cancer With Non-invasive Method Based on DNA Methylation of Circulated Tumor DNA, PBMCProstate CancerProstate AdenocarcinomaProstate Cancer MetastaticNCT03494803HKGepitherapeutics
Completed
N/A
Acceptance-Based Treatment for Prostate Cancer DistressEarly Stage Prostate CancerNCT01594593Veterans Medical Research Foundation24
Completed
N/A
Treatment of Aggressive Prostate Cancer in Real Life: Initiation, Schedule and Management of Triptorelin Treatment.Prostate CancerNCT04593420Ipsen817